In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
AbCellera Biologics Inc (NASDAQ: ABCL) closed the day trading at $2.95 up 1.37% from the previous closing price of $2.91. In other words, the price has increased by $1.37 from its previous closing price. On the day, 3.67 million shares were traded. ABCL stock price reached its highest trading level at $2.96 during the session, while it also had its lowest trading level at $2.79.
Ratios:
For a better understanding of ABCL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.34 and its Current Ratio is at 9.34. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 22, 2024, The Benchmark Company Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $9.
On December 05, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $6.KeyBanc Capital Markets initiated its Overweight rating on December 05, 2023, with a $6 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABCL now has a Market Capitalization of 871329792 and an Enterprise Value of 299590528. For the stock, the TTM Price-to-Sale (P/S) ratio is 26.44 while its Price-to-Book (P/B) ratio in mrq is 0.81. Its current Enterprise Value per Revenue stands at 9.089 whereas that against EBITDA is -1.348.
Stock Price History:
Over the past 52 weeks, ABCL has reached a high of $6.05, while it has fallen to a 52-week low of $2.34. The 50-Day Moving Average of the stock is 6.25%, while the 200-Day Moving Average is calculated to be -10.52%.
Shares Statistics:
Over the past 3-months, ABCL traded about 2.16M shares per day on average, while over the past 10 days, ABCL traded about 2525190 shares per day. A total of 295.16M shares are outstanding, with a floating share count of 221.93M. Insiders hold about 24.86% of the company’s shares, while institutions hold 34.59% stake in the company. Shares short for ABCL as of 1732838400 were 16252124 with a Short Ratio of 7.52, compared to 1730332800 on 16641378. Therefore, it implies a Short% of Shares Outstanding of 16252124 and a Short% of Float of 7.140000000000001.
Earnings Estimates
Its stock is currently analyzed by 7.0 different market analysts. The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.15 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.54 and -$0.64 for the fiscal current year, implying an average EPS of -$0.59. EPS for the following year is -$0.68, with 6.0 analysts recommending between -$0.45 and -$0.85.
Revenue Estimates
10 analysts predict $7.58M in revenue for the current quarter. It ranges from a high estimate of $11.74M to a low estimate of $4.35M. As of the current estimate, AbCellera Biologics Inc’s year-ago sales were $9.2MFor the next quarter, 10 analysts are estimating revenue of $11.81M. There is a high estimate of $22.57M for the next quarter, whereas the lowest estimate is $5.36M.
A total of 10 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $37M, while the lowest revenue estimate was $28.13M, resulting in an average revenue estimate of $31.58M. In the same quarter a year ago, actual revenue was $38.02MBased on 9 analysts’ estimates, the company’s revenue will be $43.12M in the next fiscal year. The high estimate is $96.07M and the low estimate is $19M.